Recommendations on the proper use of SGLT2 inhibitors.
出版信息
Diabetol Int. 2019 Nov 15;11(1):1-5. doi: 10.1007/s13340-019-00415-8. eCollection 2020 Jan.
Abstract
摘要
相似文献
1
Recommendations on the proper use of SGLT2 inhibitors.关于钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂正确使用的建议。
Diabetol Int. 2019 Nov 15;11(1):1-5. doi: 10.1007/s13340-019-00415-8. eCollection 2020 Jan.
2
Recommendations on the Proper Use of SGLT2 Inhibitors.关于SGLT2抑制剂正确使用的建议。
J Diabetes Investig. 2020 Jan;11(1):257-261. doi: 10.1111/jdi.13160. Epub 2019 Nov 15.
3
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.钠-葡萄糖协同转运蛋白2抑制剂相关糖尿病酮症酸中毒：临床综述及预防与诊断建议
Clin Ther. 2016 Dec;38(12):2654-2664.e1. doi: 10.1016/j.clinthera.2016.11.002.
4
SGLT2 Inhibitors May Predispose to Ketoacidosis.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂可能易引发酮症酸中毒。
J Clin Endocrinol Metab. 2015 Aug;100(8):2849-52. doi: 10.1210/jc.2015-1884. Epub 2015 Jun 18.
5
Safety of SGLT2 Inhibitors in Three Chronic Diseases.SGLT2 抑制剂在三种慢性病中的安全性。
Int Heart J. 2023;64(2):246-251. doi: 10.1536/ihj.22-441.
6
Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.确定与 SGLT2 抑制剂相关的糖尿病酮症酸中毒的风险因素：美国全国队列研究。
J Gen Intern Med. 2021 Sep;36(9):2601-2607. doi: 10.1007/s11606-020-06561-z. Epub 2021 Feb 9.
7
Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats.在 SGLT2 抑制剂治疗的大鼠中，脱水和胰岛素减少是血糖正常酮症酸中毒所必需且充分的条件。
Nat Commun. 2019 Feb 1;10(1):548. doi: 10.1038/s41467-019-08466-w.
8
Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶 4 抑制剂和磺脲类药物治疗糖尿病酮症酸中毒的安全性比较。
Diabetes Care. 2022 Apr 1;45(4):919-927. doi: 10.2337/dc21-2177.
9
Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.与 SGLT2 抑制剂治疗相关的酮症酸中毒：FAERS 数据分析。
Diabetes Metab Res Rev. 2017 Nov;33(8). doi: 10.1002/dmrr.2924. Epub 2017 Sep 29.
10
SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.SGLT2 抑制剂在伴有糖尿病肾病的 1 型糖尿病中的应用：潜在的心肾获益可能超过可预防的糖尿病酮症酸中毒风险。
Curr Diab Rep. 2022 Jul;22(7):317-332. doi: 10.1007/s11892-022-01471-2. Epub 2022 May 28.
引用本文的文献
1
Increasing Prescription of SGLT2 Inhibitors with Expanded Indications to the Elderly Population in Japan.在日本，随着适应证的扩大，老年人群中钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的处方量不断增加。
Kidney Dis (Basel). 2025 Apr 3;11(1):292-301. doi: 10.1159/000545626. eCollection 2025 Jan-Dec.
2
A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes-2nd Edition (English version).日本糖尿病学会（JDS）共识声明：2型糖尿病患者药物治疗的推荐算法 - 第2版（英文版）
Diabetol Int. 2024 Jul 11;15(3):327-345. doi: 10.1007/s13340-024-00723-8. eCollection 2024 Jul.
3
A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes - 2nd edition (English version).日本糖尿病学会共识声明：2 型糖尿病药物治疗建议算法-第 2 版（英文版）。
J Diabetes Investig. 2024 Sep;15(9):1326-1342. doi: 10.1111/jdi.14202. Epub 2024 Jul 11.
4
A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes.日本糖尿病学会（JDS）的共识声明：2型糖尿病患者药物治疗的建议算法。
Diabetol Int. 2022 Dec 23;14(1):1-14. doi: 10.1007/s13340-022-00605-x. eCollection 2023 Jan.
5
A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes.日本糖尿病学会的共识声明：2型糖尿病患者药物治疗的建议算法。
J Diabetes Investig. 2023 Jan;14(1):151-164. doi: 10.1111/jdi.13960. Epub 2022 Dec 23.
6
Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus 3 days after initiating sodium-glucose cotransporter 2 inhibitor while on an extremely low carbohydrate diet: A case report.2型糖尿病患者在开始使用钠-葡萄糖协同转运蛋白2抑制剂3天后，同时采用极低碳水化合物饮食时发生正常血糖性糖尿病酮症酸中毒：一例报告
Clin Case Rep. 2022 Nov 15;10(11):e6572. doi: 10.1002/ccr3.6572. eCollection 2022 Nov.
7
Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study.使用自发报告系统和真实世界数据库研究比较二肽基肽酶-4抑制剂与二甲双胍对主要心血管事件的影响
J Clin Med. 2022 Aug 25;11(17):4988. doi: 10.3390/jcm11174988.
8
Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan.回顾性全国研究：日本 2 型糖尿病患者一线抗糖尿病药物的趋势。
J Diabetes Investig. 2022 Feb;13(2):280-291. doi: 10.1111/jdi.13636. Epub 2021 Aug 17.
9
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.EMPA-ELDERLY试验的原理与设计：一项针对老年日本2型糖尿病患者，比较钠-葡萄糖协同转运蛋白2抑制剂恩格列净与安慰剂疗效及安全性的随机、双盲、安慰剂对照、为期52周的临床试验。
BMJ Open. 2021 Apr 7;11(4):e045844. doi: 10.1136/bmjopen-2020-045844.
10
A case in which SGLT2 inhibitor is a contributing factor to takotsubo cardiomyopathy and heart failure.1例以钠-葡萄糖协同转运蛋白2抑制剂作为应激性心肌病和心力衰竭促成因素的病例。
J Cardiol Cases. 2020 Jul 2;22(4):177-180. doi: 10.1016/j.jccase.2020.06.014. eCollection 2020 Oct.
Zotero 插件